Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary...

Logo Benzinga
Benzinga
By Pr Newswire

-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022.

-- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study in China.

-- An epidemiology study in China in 2010 showed that there were approximately 656,000 PBC patients in China including 440,000 in females over age 40. An epidemiology study in the U.S. indicated that there were approximately 120,000 PBC patients in the U.S. in 2014.

SHANGHAI, April 10, 2024 /PRNewswire/ -- Gannex Pharma Co., Ltd. (Gannex), a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the first patient dosed in the Phase II clinical trial of ASC42 to treat patients with primary biliary cholangitis (PBC).

The Phase II study (ClinicalTrials.gov Identifier: NCT05190523) consists of three ASC42 active treatment arms (5 mg, 10 mg and 15 mg) and one placebo control arm at the ratio of 1:1:1:1 and is expected to enroll a total of 100 patients who have an inadequate response to or are unable to tolerate Ursodeoxycholic acid (UDCA). The treatment duration is 12 weeks and the study is expected to be completed by the end of 2022.

The protocol of Phase III clinical trial in 210 PBC patients was approved in November 2021 by China National Medical Products Administration (NMPA). After the completion of the Phase II clinical trial, Gannex will soon initiate the Phase III trial after the communications with China NMPA in terms of drug registration related matters such as Chemistry, Manufacturing and Control (CMC) and toxicology studies.

Continue read on benzinga.com

Logo Benzinga
--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to date. Most of adverse events are grade 1 or 2. --ASC42 is...

Logo Benzinga
SAN FRANCISCO and SUZHOU, China, April 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company...

Logo Benzinga
[TODAY ONLY] For only $7, get 2 bear market beating options trade straight to your inbox and SMS every month! Click Here Now to Get Started! Four pipeline...

Logo Benzinga
LEIDEN, Netherlands, April 1, 2024 /CNW/ -- Pharming Group N.V. (Pharming or the Company) PHAR announces new data from the pivotal Phase II/III trial of...

Logo Benzinga
Lakewood-Amedex's Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022 SARASOTA, Fla., April 5, 2022...

Logo Benzinga
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi, hereinafter Meiji) today announced that the...

Logo Benzinga
Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CStone's Pipeline 2.0 Global development of CS5001 is conducted...

Logo Benzinga
[TODAY IS YOUR LUCKY DAY] Get 50% OFF and get 2 bear market beating options trade straight to your inbox and SMS every month! Click Here Now to Get Started!...

Logo Benzinga
SHANGHAI, March 23, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies...

Logo Benzinga
HANGZHOU, Chinaand SHAOXING, China, April 4, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that the first sale of its ritonavir...

Logo Benzinga
HONG KONG, April 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. ( Sirnaomics, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development...

Logo Benzinga
SAN DIEGO, March 29, 2024 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has...

Logo Benzinga
Neuro-Cells® treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following trauma The randomized,...

Logo Nasdaq
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) announced FDA has cleared the Investigational New Drug application to support a phase 2 clinical trial...

Logo Benzinga
First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both...

Logo Benzinga
LEIDEN, Netherlands, April 1, 2024 /PRNewswire/ -- Pharming Group N.V. (Pharming or the Company) PHAR announces new data from the pivotal Phase II/III trial...

Logo Benzinga
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. OCGN, a biotechnology company focused on discovering, developing, and commercializing novel...

Logo Nasdaq
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said that 12-week data from phase 3 MOONLIGHT 1 study of fezolinetant 30 mg for the nonhormonal treatment of...

Logo Benzinga
HANGZHOU and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted the marketing...

Logo Benzinga
[TODAY IS YOUR LUCKY DAY] Get 50% OFF and get 2 bear market beating options trade straight to your inbox and SMS every month! Click Here Now to Get Started!...